GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation therapy aims to slow aggressive gut and pancreatic tumors
Disease control OngoingThis study tests a treatment called PRRT (peptide receptor radionuclide therapy) using a radioactive drug (177Lu-Edotreotide) in people with aggressive neuroendocrine tumors of the stomach, intestines, or pancreas. The goal is to see if it delays tumor growth better than the curr…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
Radioactive injection shows promise in slowing neuroendocrine tumor growth
Disease control OngoingThis phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors that could not be removed by surgery. The main goal was to see which treatment delayed tumor growth…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
Could a liver artery injection boost radiation therapy for neuroendocrine tumors?
Disease control OngoingThis study tests a new method of giving a radioactive drug called Lutathera to people with neuroendocrine tumors that have spread mainly to the liver. Instead of the standard IV in the arm, the drug is injected directly into the liver artery to see if it's safe and practical. Ten…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
Lutathera safety under the microscope: 1,000+ patients monitored Long-Term
Knowledge-focused OngoingThis study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are tracking long-term side effects, including the risk of new cancers, and overall survival. The goal is to better understand the drug's safety over…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Advanced Accelerator Applications • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:05 UTC
-
Double PET scan may unlock secrets of gut tumors
Knowledge-focused OngoingThis pilot study is testing whether combining two different PET scans can give doctors a clearer picture of neuroendocrine tumors (NETs) in the gut. The scans measure how tumors take up different tracers, which may reveal whether a tumor is slow-growing or aggressive. The goal is…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:55 UTC
-
New study aims to improve life for neuroendocrine tumor patients
Knowledge-focused OngoingThis study follows over 2,500 adults with neuroendocrine tumors (NETs) to understand their symptoms, treatment decisions, and quality of life. Participants complete surveys over 18 months, and their answers are linked to medical records. The goal is to learn which treatments work…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 11, 2026 11:57 UTC